Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	84.61B
Revenue (ttm)	7.45B
Net Income (ttm)	2.46B
Shares Out	n/a
EPS (ttm)	1.50
PE Ratio	34.35
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,260
Average Volume	193,487
Open	25.55
Previous Close	24.40
Day's Range	25.41 - 25.56
52-Week Range	14.52 - 26.24
Beta	0.48
RSI	76.27
Earnings Date	Jan 30, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY